Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. - Wikidata - wikimedia - TriplyDB

Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.

Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.

http://www.wikidata.org/entity/Q36745336

about

Radiotherapy combination opportunities leveraging immunity for the next oncology practice Clinical Development of the E75 Vaccine in Breast Cancer Vaccine adjuvants as potential cancer immunotherapeutics Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Cancer vaccines Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis Adjuvants for peptide-based cancer vaccines Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Dendritic cell-based vaccine efficacy: aiming for hot spots Engineering New Approaches to Cancer Vaccines Harnessing the Microbiome to Enhance Cancer Immunotherapy Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.Laser vaccine adjuvants. History, progress, and potential Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors Antigen capture and archiving by lymphatic endothelial cells following vaccination or viral infection Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.Combinatorial contextualization of peptidic epitopes for enhanced cellular immunity.Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.Induced autoimmunity against gonadal proteins affects gonadal development in juvenile zebrafish MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth.Classification of current anticancer immunotherapies The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.Consensus nomenclature for CD8(+) T cell phenotypes in cancer Trial watch: Naked and vectored DNA-based anticancer vaccines Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.Whole-animal imaging and flow cytometric techniques for analysis of antigen-specific CD8+ T cell responses after nanoparticle vaccination.Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.Using lymph node swelling as a potential biomarker for successful vaccination.

P2860

Q26738443-675576A0-1A53-4FB7-AB02-7305E6876602 Q26745440-8290A821-BEFE-4827-B017-683C7DF1746C Q26752522-EC580E7E-DE3E-4DFB-99ED-AEC9D923E7DE Q26783488-476607CE-2142-4F3A-B676-E9E635E8999F Q26796314-70D4883E-68DC-42B3-837F-3570458929E7 Q27024438-4FBFC9A9-BC63-4018-93E6-96A83274634A Q27327288-85DCA229-D3F8-4AA9-9CD0-DDBE089573DA Q28072236-EF9266C9-CA3D-46BE-92A7-421B87DB42C0 Q28078539-BFA6FBD5-02FC-426F-A02B-1781D1C846A2 Q28082680-CB1962CD-50B5-4437-B3CD-F71C23BCEEF6 Q28085563-6E1C2864-5712-4C8C-AF87-2B7FA848CF79 Q28088598-4B247EB5-D0CA-4340-A63E-D18D5884223F Q30276128-51F7254F-54A6-4BBE-AE02-FEA238A546E0 Q30370026-C5DB5B10-299A-45A6-8F1E-55B3B3571ACA Q30371547-34C103E6-C0CB-41B9-B800-8CA90B1C3B82 Q30409722-A8961E91-5AB6-41F2-AF0F-E6D6E6D183C3 Q30412094-A4350DD1-4680-47CA-A59E-5A6FD130C053 Q30413501-7D81AB79-E1BC-49C2-9E7A-BAB45FFA85EE Q33606161-81E9C1B4-4C53-4524-8577-2E89EF33E1D1 Q33815647-4A89BA00-276D-49DC-A655-160DB3AC6037 Q33889105-2CC1A8B2-8446-428A-830A-242CC6A4B6D0 Q33902560-78A3131C-73F4-4C85-A565-57F1E56421EF Q33954123-E436A220-123C-4E8D-80AE-C771A82E467A Q34259974-095464AA-D4A0-4721-9399-A2314DADF6D8 Q34400527-8F8D2FB9-E441-4898-8428-8E7390A413C3 Q34548226-F96C0C9A-0417-41E0-8D0D-3A288A2A208D Q34601876-313D09B3-0E78-42D5-AC89-252D1FE889B6 Q34641196-943E4573-E762-4F8E-AC0D-92BED2394A46 Q35149637-6CCF0586-A336-42B5-BD13-4495850A0D10 Q35181440-B98DF806-4E04-48BE-807B-BAEA87BE38D3 Q35192883-B96640DD-73DC-42F4-AA44-4BEA785A0C71 Q35201915-4DBCE93A-00FA-4D71-A3D1-0655B43F9757 Q35569528-9E5F8537-01B5-46A7-94FC-BDD976E7A9D9 Q35798822-E2D45CE2-2098-43EC-AB46-B04E819F37F8 Q35798986-CAD42351-9F88-4A64-8AB6-7D2D853925B5 Q35864569-E2FFE580-57F7-420D-BD28-EFEA327B2B7F Q35886450-8470C967-5F58-4905-8B42-3CF27D18819B Q35970758-42F8528B-D257-44CE-830A-EFBF785D1468 Q36018407-965F76E4-F9FC-4ED8-8CCC-35CB5290D96D Q36032562-9B0A376D-D826-42B9-910E-A08332EA7E9A

P2860

Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.

http://www.wikidata.org/entity/Q36745336

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Persistent antigen at vaccinat ...... ion, dysfunction and deletion.

@ast

Persistent antigen at vaccinat ...... ion, dysfunction and deletion.

@en

type

label

Persistent antigen at vaccinat ...... ion, dysfunction and deletion.

@ast

Persistent antigen at vaccinat ...... ion, dysfunction and deletion.

@en

prefLabel

Persistent antigen at vaccinat ...... ion, dysfunction and deletion.

@ast

Persistent antigen at vaccinat ...... ion, dysfunction and deletion.

@en

P1433

Q36745336-038D13E8-D601-42F0-BEA9-8F0C56EE0081

P1476

Q36745336-B04A2532-BB80-452A-A3FA-2A5221D8263B

P2093

Q36745336-12F6EFBF-AC20-498C-9146-1C22E115A886

Q36745336-278EEA47-1950-4C46-84E1-5C7EBD4E05A5

Q36745336-391A37EC-8995-4B23-84F9-69E4A4AEE1C3

Q36745336-3E78AD93-CFDE-403E-A8A0-D2B5B4A48F58

Q36745336-46913988-4605-482C-9835-C7ABD105666D

Q36745336-5023B345-7823-4DA7-986A-63D2E1B3F760

Q36745336-588079DB-A3A0-4DF9-8EE2-1D7199BE1CA8

Q36745336-5E0E5C8D-3A42-485B-9FCC-090FF298E4B6

Q36745336-5ED13503-7798-4812-84F0-7D6E717CBCFF

Q36745336-65EF2537-3579-4A3F-9B89-C9BDBF6F505A

P2860

Q36745336-03BD5320-EBBD-4D7D-9ED5-1D9998E5363E

Q36745336-081A7374-5E31-4F4F-96FD-3868E08B8C7B

Q36745336-13F38FDE-8303-41C4-9F46-9B791A6AEE9B

Q36745336-1DB46A6E-A975-40C3-8B0E-3AAFF89BE0A0

Q36745336-20663DA6-7817-4B57-ADF3-DBE0EBC5C327

Q36745336-207318DE-43E5-47CB-A8EF-BABFB1F78356

Q36745336-25D50816-59D8-4A5D-8438-7EDDBB69B3E6

Q36745336-29CC52E5-79C7-4628-8012-AF12AF8B967A

Q36745336-3461233D-11A2-48C6-95FA-2C7852AE6E86

Q36745336-3C2061AD-8F6B-487A-BC66-1872DD62F6BF

P2888

Q36745336-EE53E00F-8D78-448F-83DD-AAEDE070DB91

P304

Q36745336-9E888E70-6D84-4A0A-8222-EAEA90F54F63

P31

Q36745336-20ADDA08-D07E-422C-99DC-E493592C7E3B

P356

Q36745336-DC8C5914-81F6-428A-8619-6C2B05FB2653

P407

Q36745336-B49EAEA5-02C1-4BFC-99F1-3F1505CD44FA

P433

Q36745336-BB99821A-C414-4AC5-87A7-1D9E2943143C

P478

Q36745336-B3814856-F6B2-4994-ACE1-748DE232131C

P577

Q36745336-CC68D93F-9FD4-4998-B486-2EA6A7411B6C

P5875

Q36745336-0A3991D4-A0BC-4BD2-8B73-4355016AD447

P698

Q36745336-03EC3358-2FB5-48AC-AD00-61F2FE51C659

P932

Q36745336-DD625BD9-DB78-498D-9677-034C81365BCD

P356

P1433

Nature Medicine

P1476

Persistent antigen at vaccinat ...... ion, dysfunction and deletion.

@en

P2093

Brian Rabinovich

http://www.w3.org/2001/XMLSchema#string

Chengwen Liu

http://www.w3.org/2001/XMLSchema#string

Giovanni Nitti

http://www.w3.org/2001/XMLSchema#string

Kimberly S Schluns

http://www.w3.org/2001/XMLSchema#string

Miguel A Medina

http://www.w3.org/2001/XMLSchema#string

Nathaniel R Greeley

http://www.w3.org/2001/XMLSchema#string

Nina Jaffarzad

http://www.w3.org/2001/XMLSchema#string

Patrick Hwu

http://www.w3.org/2001/XMLSchema#string

Richard E Davis

http://www.w3.org/2001/XMLSchema#string

Ryan T Sowell

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Cancer immunotherapy: moving beyond current vaccines

Cluster analysis and display of genome-wide expression patterns

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Myeloid-derived suppressor cells as regulators of the immune system

Coordinated regulation of myeloid cells by tumours

Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity

T cell exhaustion

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

P2888

P304

465-472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3105

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235776740

http://www.w3.org/2001/XMLSchema#string

P698

23455713

http://www.w3.org/2001/XMLSchema#string

P932

3618499

http://www.w3.org/2001/XMLSchema#string